Mostrar el registro sencillo del ítem

dc.contributor.authorKissling, Esther
dc.contributor.authorPozo Sanchez, Francisco 
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorBuda, Silke
dc.contributor.authorVilcu, Ana-Maria
dc.contributor.authorDomegan, Lisa
dc.contributor.authorMazagatos, Clara 
dc.contributor.authorDijkstra, Frederika
dc.contributor.authorLatorre-Margalef, Neus
dc.contributor.authorKurečić Filipović, Sanja
dc.contributor.authorMachado, Ausenda
dc.contributor.authorLazar, Mihaela
dc.contributor.authorCasado, Itziar
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorvan der Werf, Sylvie
dc.contributor.authorO'Donnell, Joan
dc.contributor.authorLinares Dopido, Juan Antonio
dc.contributor.authorMeijer, Adam
dc.contributor.authorRiess, Maximilian
dc.contributor.authorVišekruna Vučina, Vesna
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorMihai, Maria Elena
dc.contributor.authorCastilla Catalán, Jesús
dc.contributor.authorGoerlitz, Luise
dc.contributor.authorFalchi, Alessandra
dc.contributor.authorConnell, Jeff
dc.contributor.authorCastrillejo, Daniel
dc.contributor.authorHooiveld, Mariette
dc.contributor.authorCarnahan, Annasara
dc.contributor.authorIlić, Maja
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorIvanciuc, Alina
dc.contributor.authorMaurel, Marine
dc.contributor.authorOmokanye, Ajibola
dc.contributor.authorValenciano, Marta
dc.contributor.authorI-MOVE study team
dc.date.accessioned2023-02-07T12:42:46Z
dc.date.available2023-02-07T12:42:46Z
dc.date.issued2023-01
dc.identifier.citationInfluenza Other Respir Viruses. 2023 Jan;17(1):e13069.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15465
dc.description.abstractBackground: In 2021-2022, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure influenza vaccine effectiveness (VE). Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT-PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions. Results: Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43-89) and 81% (95% CI: 45-93) among those aged 15-64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12-42) and 25% (95% CI: -41 to 61), 33% (95% CI: 14-49), and 26% (95% CI: -22 to 55) among those aged 0-14, 15-64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: -6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2. Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021-2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza.es_ES
dc.description.sponsorshipThis project has received funding from the European Centre for Disease Prevention and Control with in the framework contract ECDC/2018/029.es_ES
dc.language.isoenges_ES
dc.publisherWiley es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectEuropees_ES
dc.subjectInfluenzaes_ES
dc.subjectInfluenza vaccinees_ES
dc.subjectMulticentre studyes_ES
dc.subjectVaccine effectivenesses_ES
dc.subject.meshInfluenza A Virus, H1N1 Subtype es_ES
dc.subject.meshInfluenza Vaccines es_ES
dc.subject.meshInfluenza, Humanes_ES
dc.subject.meshHumans es_ES
dc.subject.meshCase-Control Studies es_ES
dc.subject.meshEurope es_ES
dc.subject.meshInfluenza A Virus, H3N2 Subtype es_ES
dc.subject.meshPrimary Health Care es_ES
dc.subject.meshVaccination es_ES
dc.subject.meshVaccine Efficacyes_ES
dc.subject.meshMale es_ES
dc.subject.meshFemale es_ES
dc.subject.meshInfant, Newborn es_ES
dc.subject.meshInfant es_ES
dc.subject.meshChild, Preschool es_ES
dc.subject.meshChild es_ES
dc.subject.meshAdolescent es_ES
dc.subject.meshYoung Adult es_ES
dc.subject.meshAdult es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshAged es_ES
dc.titleInfluenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre studyes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID36702797es_ES
dc.format.volume17es_ES
dc.format.number1es_ES
dc.format.pagee13069es_ES
dc.identifier.doi10.1111/irv.13069es_ES
dc.contributor.funderUnión Europea. European Centre for Disease Prevention and Control (ECDC) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1750-2659es_ES
dc.relation.publisherversionhttps://doi.org/10.1111/irv.13069es_ES
dc.identifier.journalInfluenza and other respiratory viruseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/ECDC/2018/029es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional